{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T19:51:19Z","timestamp":1782330679430,"version":"3.54.5"},"reference-count":40,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Emergency Medicine Clinics of North America"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.emc.2026.01.005","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T21:17:05Z","timestamp":1778188625000},"page":"495-505","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antivirals Improve Outcomes in Influenza"],"prefix":"10.1016","volume":"44","author":[{"given":"Tonmoy","family":"Shanto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuf","family":"Zarhiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaclyn","family":"Dibello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbas","family":"Husain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.emc.2026.01.005_bib1","series-title":"Influenza (seasonal)","year":"2025"},{"key":"10.1016\/j.emc.2026.01.005_bib2","series-title":"Preliminary estimated flu disease burden 2023\u20132024 flu season","year":"2024"},{"key":"10.1016\/j.emc.2026.01.005_bib3","series-title":"Flu burden prevented by vaccination, 2023\u20132024 flu season","year":"2025"},{"key":"10.1016\/j.emc.2026.01.005_bib4","author":"Stuart"},{"issue":"12","key":"10.1016\/j.emc.2026.01.005_bib5","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.cmi.2016.07.007","article-title":"Functional balance between neuraminidase and haemagglutinin in influenza viruses","volume":"22","author":"Gaymard","year":"2016","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"10.1016\/j.emc.2026.01.005_bib6","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/rmv.1879","article-title":"A new role of neuraminidase (NA) in the influenza virus life cycle: implication for developing NA inhibitors with novel mechanism of action","volume":"26","author":"Yang","year":"2016","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.emc.2026.01.005_bib7","author":"Pokusai"},{"issue":"2","key":"10.1016\/j.emc.2026.01.005_bib8","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.bbamem.2010.04.015","article-title":"Influenza M2 proton channels","volume":"1808","author":"Pielak","year":"2011","journal-title":"Biochim Biophys Acta"},{"issue":"6","key":"10.1016\/j.emc.2026.01.005_bib9","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/rmv.666","article-title":"Structure of influenza virus ribonucleoprotein complexes and their packaging into virions","volume":"20","author":"Noda","year":"2010","journal-title":"Rev Med Virol"},{"issue":"1","key":"10.1016\/j.emc.2026.01.005_bib10","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3390\/microorganisms11010183","article-title":"Influenza treatment: limitations of antiviral therapy and advantages of drug combination therapy","volume":"11","author":"Batool","year":"2023","journal-title":"Microorganisms"},{"issue":"31","key":"10.1016\/j.emc.2026.01.005_bib11","doi-asserted-by":"crossref","first-page":"13866","DOI":"10.1073\/pnas.1002051107","article-title":"Coexistence of two adamantane binding sites in the influenza A M2 ion channel","volume":"107","author":"Rosenberg","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.emc.2026.01.005_bib12","doi-asserted-by":"crossref","DOI":"10.1177\/20587384211002621","article-title":"A review: mechanism of action of antiviral drugs","volume":"35","author":"Kausar","year":"2021","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"4","key":"10.1016\/j.emc.2026.01.005_bib13","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1128\/AAC.23.4.577","article-title":"Reduction in fever and symptoms in young adults with influenza A\/Brazil\/78 H1N1 infection after treatment with aspirin or amantadine","volume":"23","author":"Younkin","year":"1983","journal-title":"Antimicrob Agents Chemother"},{"issue":"9492","key":"10.1016\/j.emc.2026.01.005_bib14","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S0140-6736(05)67338-2","article-title":"Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern","volume":"366","author":"Bright","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.emc.2026.01.005_bib15","series-title":"Influenza antiviral medications: summary for clinicians","year":"2023"},{"issue":"Suppl 2","key":"10.1016\/j.emc.2026.01.005_bib16","doi-asserted-by":"crossref","first-page":"S119","DOI":"10.1086\/507552","article-title":"Antiviral management of seasonal and pandemic influenza","volume":"194","author":"Hayden","year":"2006","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.emc.2026.01.005_bib17","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.antiviral.2013.03.014","article-title":"Influenza virus resistance to neuraminidase inhibitors","volume":"98","author":"Samson","year":"2013","journal-title":"Antiviral Res"},{"issue":"4","key":"10.1016\/j.emc.2026.01.005_bib18","doi-asserted-by":"crossref","first-page":"761","DOI":"10.2165\/00003495-199958040-00016","article-title":"Zanamivir: a review of its use in influenza","volume":"58","author":"Dunn","year":"1999","journal-title":"Drugs"},{"issue":"13","key":"10.1016\/j.emc.2026.01.005_bib19","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1056\/NEJMra050740","article-title":"Neuraminidase inhibitors for influenza","volume":"353","author":"Moscona","year":"2005","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.emc.2026.01.005_bib20","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.3390\/molecules21111513","article-title":"Influenza neuraminidase inhibitors: synthetic approaches, derivatives and biological activity","volume":"21","author":"Laborda","year":"2016","journal-title":"Molecules"},{"key":"10.1016\/j.emc.2026.01.005_bib21","article-title":"Durham drugmaker receives $7M boost from feds for flu therapy","author":"Ezzone Z","year":"2022","journal-title":"Triangle Business Journal"},{"issue":"Suppl 1","key":"10.1016\/j.emc.2026.01.005_bib22","doi-asserted-by":"crossref","first-page":"S764","DOI":"10.1093\/ofid\/ofy229.2190","article-title":"Phase 3 trial of Baloxavir Marboxil in high-risk influenza patients (CAPSTONE-2 Study)","volume":"5","author":"Ison","year":"2018","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"10.1016\/j.emc.2026.01.005_bib23","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/irv.12794","article-title":"Intravenous peramivir vs oral oseltamivir in high-risk emergency department patients with influenza: results from a pilot randomized controlled study","volume":"15","author":"Hsieh","year":"2021","journal-title":"Influenza Other Respir Viruses"},{"key":"10.1016\/j.emc.2026.01.005_bib24","series-title":"StatPearls","article-title":"Influenza","author":"Boktor","year":"2023"},{"key":"10.1016\/j.emc.2026.01.005_bib25","series-title":"Flu: what to Do if you get sick","year":"2024"},{"issue":"9979","key":"10.1016\/j.emc.2026.01.005_bib26","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/S0140-6736(15)60074-5","article-title":"Influenza: the rational use of oseltamivir","volume":"385","author":"Kelly","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.emc.2026.01.005_bib27","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1001\/jamainternmed.2024.7193","article-title":"Antiviral medications for treatment of nonsevere influenza: a systematic review and network meta-analysis","volume":"185","author":"Gao","year":"2025","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.emc.2026.01.005_bib28","series-title":"Clinical Practice Guidelines for influenza","year":"2024"},{"issue":"5","key":"10.1016\/j.emc.2026.01.005_bib29","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S2213-2600(14)70041-4","article-title":"Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data","volume":"2","author":"Muthuri","year":"2014","journal-title":"Lancet Respir Med"},{"issue":"10","key":"10.1016\/j.emc.2026.01.005_bib30","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1086\/656740","article-title":"The infection attack rate and severity of 2009 pandemic H1N1 influenza in Hong Kong","volume":"51","author":"Wu","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.emc.2026.01.005_bib31","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.mayocpiqo.2019.12.005","article-title":"Decreased hospital length of stay with early administration of oseltamivir in patients hospitalized with influenza","volume":"4","author":"Dou","year":"2020","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"issue":"2","key":"10.1016\/j.emc.2026.01.005_bib32","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1093\/cid\/ciae427","article-title":"Timing of influenza antiviral therapy and risk of death in adults hospitalized with influenza-associated pneumonia, influenza hospitalization surveillance network (FluSurv-NET), 2012\u20132019","volume":"80","author":"Tenforde","year":"2025","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.emc.2026.01.005_bib33","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1517\/14740338.5.5.603","article-title":"Safety of neuraminidase inhibitors for influenza","volume":"5","author":"Jones","year":"2006","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"10.1016\/j.emc.2026.01.005_bib34","article-title":"Neuraminidase inhibitors for preventing and treating influenza in adults and children","author":"Jefferson","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.emc.2026.01.005_bib35","first-page":"337","article-title":"Baloxavir and treatment-emergent resistance: public health insights and next steps","volume":"221","author":"Gubareva","year":"2020","journal-title":"J Infect Dis"},{"issue":"Suppl 2","key":"10.1016\/j.emc.2026.01.005_bib36","first-page":"ii5","article-title":"Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations","volume":"65","author":"Davies","year":"2010","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"10.1016\/j.emc.2026.01.005_bib37","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s10096-020-03840-9","article-title":"Influenza and antiviral resistance: an overview","volume":"39","author":"Lampejo","year":"2020","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"9","key":"10.1016\/j.emc.2026.01.005_bib38","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1093\/cid\/cis1220","article-title":"Global assessment of resistance to neuraminidase inhibitors, 2008\u20132011: the Influenza Resistance Information Study (IRIS)","volume":"56","author":"Whitley","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.emc.2026.01.005_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2025.106217","article-title":"Global update on the susceptibilities of influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2020\u20132023","volume":"241","author":"Hussain","year":"2025","journal-title":"Antiviral Res"},{"issue":"9979","key":"10.1016\/j.emc.2026.01.005_bib40","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/S0140-6736(14)62449-1","article-title":"Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials","volume":"385","author":"Dobson","year":"2015","journal-title":"Lancet"}],"container-title":["Emergency Medicine Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733862726000052?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733862726000052?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T19:41:01Z","timestamp":1782330061000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733862726000052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0733862726000052"],"URL":"https:\/\/doi.org\/10.1016\/j.emc.2026.01.005","relation":{},"ISSN":["0733-8627"],"issn-type":[{"value":"0733-8627","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antivirals Improve Outcomes in Influenza","name":"articletitle","label":"Article Title"},{"value":"Emergency Medicine Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.emc.2026.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}